Forum Finance Group’s Cartesian Therapeutics RNAC Stock Holding History

Forum Finance Group’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33K	Hold	3,900	–	–	0.01%	252
2026 Q1	$20K	Buy	+3,900	New	+$27.8K	0.01%	242

Other funds holding RNAC

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Forum Finance Group's RNAC Position: Q2 2026 in Review

Forum Finance Group held its Cartesian Therapeutics (RNAC) position steady in Q2 2026 at 3,900 shares worth $33K. The position accounts for 0.01% of the portfolio, ranked #252.

Forum Finance Group first reported a position in RNAC in Q1 2026 and has held it in 2 quarters since. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

Forum Finance Group held 3,900 shares of Cartesian Therapeutics worth $33K as of Q2 2026.
Forum Finance Group left its Cartesian Therapeutics share count unchanged in Q2 2026.
Cartesian Therapeutics made up 0.01% of Forum Finance Group's portfolio in Q2 2026, its #252 holding.
Forum Finance Group first reported a position in Cartesian Therapeutics in Q1 2026 and has held it in 2 quarters since.
95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Forum Finance Group's 13F filing for Q2 2026, filed 14 Aug 2026.